Healthcare / Medical Instruments & SuppliesShenzhen
$12.74
+0.10 (+0.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-61.4M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.5B
P/E
N/A
•EV/EBITDA
43.4x
↑ROE
-2.1%
↓Gross Margin
11.1%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.7%
FCF CAGR
—
FCF margin
-7.9%
FCF / Net income
1.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.37B · net income $-112.4M · FCF $-186.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.37B | $2.37B | $2.46B | $2.11B | $1.57B |
| Net Income | $-112.4M | $-112.4M | $-87.1M | $-130.9M | $66.9M |
| EBITDA | $130.1M | $130.1M | $176.7M | $84.2M | $200.8M |
| EPS | -0.26 | -0.26 | -0.20 | -0.31 | 0.15 |
| Gross Margin | 11.1% | 11.1% | 13.4% | 12.1% | 9.7% |
| Operating Margin | -2.2% | -2.2% | 1.5% | 0.2% | 0.7% |
| Net Margin | -4.7% | -4.7% | -3.5% | -6.2% | 4.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.16 | 0.09 | 0.01 |
| Current Ratio | 2.32 | 2.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-186.9M | $-186.9M | $76.5M | $-61.4M | $-100.9M |
| Returns | |||||
| ROE | -2.1% | -2.1% | -1.6% | -2.3% | 1.1% |
| Valuation | |||||
| P/E | — | — | — | — | 85.16 |
| EV/EBITDA | 43.37 | 43.37 | 29.00 | 68.76 | 26.30 |
| P/B | 1.05 | 1.05 | 0.88 | 1.05 | 0.93 |
| Growth & Yield | |||||
| Revenue Growth | -3.4% | -3.4% | 16.7% | 33.9% | — |
| EPS Growth | -30.0% | -30.0% | 35.3% | -300.0% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.20 → -0.26
Residual
+11.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.